Low-dose PEG-IFN.ALPHA.2a maintenance therapy significantly reduces serum levels of ALT and AFP in chronic hepatitis C patients compared to glycyrrhizin

DOI Web Site Web Site 3 Citations 22 References
  • Sumida Yoshio
    Center for Digestive and Liver Diseases, Nara City Hospital
  • Nakamura Takefumi
    Department of Gastroenterology and Hepatology, Kansai Electric Power Company Hospital
  • Kobata Tatsuro
    Department of Gastroenterology and Hepatology, Uji Tokushukai Hospital
  • Sando Takehiro
    Center for Digestive and Liver Diseases, Hoshigaoka Koseinenkin Hospital
  • Nabeshima Motoshige
    Department of Gastroenterology and Hepatology, Tenri Yorozu Hospital
  • Oyamada Hirokazu
    Department of Gastroenterology, Matsushita Memorial Hospital
  • Arai Masahiro
    Department of Gastroenterology and Hepatology, Yamashiro Public Hospital
  • Kawasaki Toshihiko
    Department of Gastroenterology and Endocrinology, Nara Hospital Kinki University Faculty of Medicine
  • Katsushima Shinji
    Department of Gastroenterology, Kyoto Medical Center, National Hospital Organization

Bibliographic Information

Other Title
  • Ｃ型慢性肝炎に対するペグインターフェロンα２ａ少量療法はグリチルリチン製剤に比して有意にＡＬＴ値およびＡＦＰ値を低下させる
  • Cガタ マンセイ カンエン ニ タイスル ペグインターフェロン アルファ 2a ショウリョウ リョウホウ ワ グリチルリチン セイザイ ニ ヒシテ ユウイ ニ ALTチ オヨビ AFPチ オ テイカ サセル
  • Low-dose PEG-IFNα2a maintenance therapy significantly reduces serum levels of ALT and AFP in chronic hepatitis C patients compared to glycyrrhizin

Search this article

Description

Sixty-four CHC patients were treated with low-dose PEG-IFN maintenance therapy (median initial dose of 90 μg/wk for longer than 24 wks) or SNMC (median initial dose of 170 ml/wk for longer than 24 wks) at nine hepatology centers. The median observation period was 154 wks in the PEG-IFN group and 145 wks in the SNMC group. The ALT levels (median, IU/L) at baseline and at wks 24 and 48 were 64, 34 and 30 in the PEG-IFN group and 80, 47 and 52 in the SNMC group, respectively. The AFP levels (median, ng/mL) at baseline, wks 24 and 48 were 12, 9.2 and 7.2 in the PEG-IFN group and 12, 12.5 and 18 in the SNMC group, respectively. More patients had AFP <10 ng/mL in the PEG-IFN group than in the SNMC group. HCC developed in three patients (8%) in the PEG-IFN group and in three patients (11%) in the SNMC group. Platelet counts, hemoglobin levels and white cell counts during the treatment period were significantly lower in the PEG-IFN group than in the SNMC group, but all of the patients were able to continue treatment following dose modifications.<br>

Journal

  • Kanzo

    Kanzo 52 (10), 644-651, 2011

    The Japan Society of Hepatology

Citations (3)*help

See more

References(22)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top